Skip to content

Vivani Medical VANI Free cash flow yield

Free cash flow yield at other companies

Eli Lilly logo
Eli LillyLLY
1.4%+0.9pp
Amgen logo
AmgenAMGN
4.5%-2.0pp
Altimmune logo
AltimmuneALT
-12.5%+20.3pp
Wave Life Sciences logo
Wave Life SciencesWVE
-13.6%-0.9pp
Prime Medicine logo
Prime MedicinePRME
-25.3%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-9.3%-4.3pp

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Calculated from Vivani Medical’s reported figures.

Based on trailing twelve months.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's free cash flow yield?
Vivani Medical (VANI) reported free cash flow yield of -31.3% in Q1 2026.
How has Vivani Medical's free cash flow yield changed year-over-year?
Vivani Medical's free cash flow yield decreased by 0.4% year-over-year, from -31.2% to -31.3%.
What is the long-term trend for Vivani Medical's free cash flow yield?
Over 4 years (2020 to 2025), Vivani Medical's free cash flow yield has grown at a 32.4% compound annual growth rate (CAGR), from -9.2% to -28.4%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.